{"id":6507,"date":"2020-12-14T14:27:00","date_gmt":"2020-12-14T14:27:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6507"},"modified":"2024-05-02T10:08:12","modified_gmt":"2024-05-02T08:08:12","slug":"efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/","title":{"rendered":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial"},"content":{"rendered":"
\n

Makoto Naganuma<\/a>,\u00a0Yoko Yokoyama<\/a>,\u00a0Satoshi Motoya<\/a>,\u00a0Kenji Watanabe<\/a>,\u00a0Koji Sawada<\/a>,\u00a0Fumito Hirai<\/a>,\u00a0Takayuki Yamamoto<\/a>,\u00a0Hiroyuki Hanai<\/a>,\u00a0Teppei Omori<\/a>,\u00a0Takanori Kanai<\/a>\u00a0&\u00a0Toshifumi Hibi<\/a>, Journal of Gastroenterology<\/em><\/a>\u00a0volume\u00a055<\/strong>,\u00a0pages390\u2013400 (2020)<\/p>\n<\/div>\n\n

\n

Apheresis was well tolerated as maintenance therapy for UC although the cumulative clinical remission rate at 12\u00a0months was comparable between the apheresis and control groups.<\/p>\n<\/div>\n\n

\n

Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter <\/a>https:\/\/link.springer.com\/article\/10.1007\/s00535-019-01651-0#group-1<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Makoto Naganuma,\u00a0Yoko Yokoyama,\u00a0Satoshi Motoya,\u00a0Kenji Watanabe,\u00a0Koji Sawada,\u00a0Fumito Hirai,\u00a0Takayuki Yamamoto,\u00a0Hiroyuki Hanai,\u00a0Teppei Omori,\u00a0Takanori Kanai\u00a0&\u00a0Toshifumi Hibi, Journal of Gastroenterology\u00a0volume\u00a055,\u00a0pages390\u2013400 (2020) Apheresis was well tolerated as maintenance therapy for UC although the cumulative clinical remission rate at 12\u00a0months was comparable between the apheresis and control groups. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label […]<\/p>\n","protected":false},"template":"","scientific_tags":[337,147,459,96,189,306],"class_list":["post-6507","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-apheresis","scientific_tags-clinical-remission","scientific_tags-control-trial","scientific_tags-open-label","scientific_tags-randomised","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"https:\/\/link.springer.com\/article\/10.1007\/s00535-019-01651-0#group-1<\/a>"},"yoast_head":"\nEfficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Makoto Naganuma,\u00a0Yoko Yokoyama,\u00a0Satoshi Motoya,\u00a0Kenji Watanabe,\u00a0Koji Sawada,\u00a0Fumito Hirai,\u00a0Takayuki Yamamoto,\u00a0Hiroyuki Hanai,\u00a0Teppei Omori,\u00a0Takanori Kanai\u00a0&\u00a0Toshifumi Hibi, Journal of Gastroenterology\u00a0volume\u00a055,\u00a0pages390\u2013400 (2020) Apheresis was well tolerated as maintenance therapy for UC although the cumulative clinical remission rate at 12\u00a0months was comparable between the apheresis and control groups. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T08:08:12+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/\",\"name\":\"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2020-12-14T14:27:00+00:00\",\"dateModified\":\"2024-05-02T08:08:12+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/","og_locale":"es_ES","og_type":"article","og_title":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte","og_description":"Makoto Naganuma,\u00a0Yoko Yokoyama,\u00a0Satoshi Motoya,\u00a0Kenji Watanabe,\u00a0Koji Sawada,\u00a0Fumito Hirai,\u00a0Takayuki Yamamoto,\u00a0Hiroyuki Hanai,\u00a0Teppei Omori,\u00a0Takanori Kanai\u00a0&\u00a0Toshifumi Hibi, Journal of Gastroenterology\u00a0volume\u00a055,\u00a0pages390\u2013400 (2020) Apheresis was well tolerated as maintenance therapy for UC although the cumulative clinical remission rate at 12\u00a0months was comparable between the apheresis and control groups. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T08:08:12+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/","name":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2020-12-14T14:27:00+00:00","dateModified":"2024-05-02T08:08:12+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-of-apheresis-as-maintenance-therapy-for-patients-with-ulcerative-colitis-in-an-open-label-prospective-multicenter-randomised-controlled-trial\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/6507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=6507"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=6507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}